Skip to main content
. 2012 Sep 25;7(9):e46000. doi: 10.1371/journal.pone.0046000

Figure 1. Study design and sample number for each step of the assay.

Figure 1

94 NED and 93 CRC plasma samples were collected. Forty patient samples (16 NED and 24 CRC) were measured twice for SEPT9 validation purposes. 2 NED and 1 CRC samples yielded both Septin 9 positive and negative results; hence they were excluded from the study. Furthermore samples for FOBT and CEA were collected retrospectively. CRC = colorectal cancer; NED = no evidence of disease (healthy control); SEPT9 = Septin 9.